
Sign up to save your podcasts
Or
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
4.8
6262 ratings
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
1,284 Listeners
2,162 Listeners
1,043 Listeners
978 Listeners
1,795 Listeners
2,288 Listeners
3,989 Listeners
121 Listeners
318 Listeners
5,958 Listeners
1,543 Listeners
30 Listeners
144 Listeners
18 Listeners
50 Listeners